(Q37462566)

20 August 2017

title

Reactivation of hepatitis B. (English)

1 reference

20 August 2017

Jay H Hoofnagle

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

49

1 reference

20 August 2017

issue

5 Suppl

1 reference

20 August 2017

page(s)

S156-65

1 reference

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy

20 August 2017

cites work

1 reference

7 January 2021

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

1 reference

7 January 2021

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

1 reference

7 January 2021

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

1 reference

7 January 2021

Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab

1 reference

7 January 2021

Reactivation of hepatitis B virus by corticosteroids in a case of idiopathic nephrotic syndrome

1 reference

7 January 2021

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

1 reference

7 January 2021

Hepatitis B virus reactivation or reinfection associated with HIV-1 infection

1 reference

7 January 2021

Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area.

1 reference

7 January 2021

Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation

1 reference

7 January 2021

Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection

1 reference

7 January 2021

Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

1 reference

7 January 2021

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

1 reference

7 January 2021

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

1 reference

7 January 2021

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

1 reference

7 January 2021

Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report

1 reference

7 January 2021

Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge

1 reference

7 January 2021

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

1 reference

7 January 2021

Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

1 reference

7 January 2021

HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

1 reference

7 January 2021

Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy

1 reference

7 January 2021

Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations

1 reference

7 January 2021

Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab

1 reference

7 January 2021

Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab

1 reference

7 January 2021

Fatal reactivation of hepatitis B after chemotherapy for lymphoma.

1 reference

7 January 2021

Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy

1 reference

7 January 2021

Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient

1 reference

7 January 2021

Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

1 reference

7 January 2021

Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection

1 reference

7 January 2021

Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.

1 reference

7 January 2021

Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy

1 reference

7 January 2021

Natural History of Hepatitis B Virus Infection in Renal Transplant Recipients-A Fifteen-Year Follow-Up

1 reference

7 January 2021

Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients.

1 reference

7 January 2021

Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine

1 reference

7 January 2021

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

7 January 2021

Infectivity of hepatic allografts with antibodies to hepatitis B virus

1 reference

7 January 2021

De novo hepatitis B after liver transplantation from hepatitis B core antibody—Positive donors in an area with high prevalence of anti-HBc positivity in the donor population

1 reference

7 January 2021

Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants

1 reference

7 January 2021

Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen

1 reference

7 January 2021

Long-term histologic and virologic outcomes of acute self-limited hepatitis B.

1 reference

7 January 2021

Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen

1 reference

7 January 2021

Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors

1 reference

7 January 2021

Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy

1 reference

7 January 2021

Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation

1 reference

7 January 2021

Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation

1 reference

7 January 2021

Safe use of livers from donors with positive hepatitis B core antibody

1 reference

7 January 2021

Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.

1 reference

7 January 2021

Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc

1 reference

7 January 2021

Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal

1 reference

7 January 2021

Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation

1 reference

7 January 2021

Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients

1 reference

7 January 2021

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

1 reference

7 January 2021

Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy

1 reference

7 January 2021

Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?

1 reference

7 January 2021

Spontaneous reactivation of hepatitis B in Chinese patients with HBsAg-positive chronic active hepatitis

1 reference

7 January 2021

Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis.

1 reference

7 January 2021

Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients

1 reference

7 January 2021

Reactivation of chronic type B hepatitis presenting as acute viral hepatitis

1 reference

7 January 2021

Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection

1 reference

7 January 2021

Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV

1 reference

7 January 2021

Reappearance of Hepatitis B Virus in Immune Patients Infected with the Human Immunodeficiency Virus Type 1

1 reference

7 January 2021

Reactivation of hepatitis B in AIDS

1 reference

7 January 2021

Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal

1 reference

7 January 2021

Hepatitis B reactivation after lamivudine

1 reference

7 January 2021

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

1 reference

7 January 2021

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial

1 reference

7 January 2021

Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection

1 reference

7 January 2021

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

1 reference

7 January 2021

Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors.

1 reference

7 January 2021

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.

1 reference

7 January 2021

Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy

1 reference

7 January 2021

Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients

1 reference

7 January 2021

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

1 reference

7 January 2021

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.22945

1 reference

20 August 2017

1 reference